Inhibition of the human chemokine receptor CXCR4 by antisense phosphorothioate oligodeoxyribonucleotides
A Kusunoki1, T Saitou, N Miyano-Kurosaki
1Department of Industrial Chemistry, Chiba Institute of Technology, Narashino, Chiba, Japan.
Abstract:
The CXC chemokine receptor CXCR4/fusion, a major coreceptor for the T-cell line T-tropic (X4) HIV-1 virus, plays a critical role in T-tropic virus fusion and entry into permissive cells. In the present study, we describe the effects of an antisense phosphorothioate oligodeoxyribonucleotide (anti-S-ODN) on the inhibition of CXCR4 gene expression in X4 HIV-1 infected HeLa-CD4 cells, to find more efficacious therapeutic possibilities for human immunodeficiency virus type 1 (HIV-1) infection. The naked antisense phosphorothioate oligodeoxyribonucleotide (anti-S-ODN-1), containing the AUG initiation codon at the center of the oligodeoxyribonucleotide, showed a slightly higher inhibitory effect on HIV-1 gag p24 production among all sequences tested. We also examined the concomitant use of a basic peptide transfection reagent, nucleosomal histone proteins (RNP), for the delivery of the anti-S-ODN-1. The anti-S-ODN-1 encapsulated with RNP had higher inhibitory effects on p24 products than the naked anti-S-ODN-1. When the anti-S-ODN-1 encapsulated with RNP was incubated with HeLa-CD4 cells, the surface levels of this chemokine receptor showed high suppression, indicating sequence-specific inhibition. The activities of unmodified oligodeoxyribonucleotide are effectively enhanced by using a basic peptide, RNP.
Insights
An antisense oligodeoxynucleotide targeting CXCR4 gene expression inhibited HIV-1 replication. Delivery with RNP enhanced this inhibition, offering a potential therapeutic strategy for HIV-1 infection.
Area of Science:
- Virology
- Molecular Biology
- Drug Discovery
Background:
- CXC chemokine receptor CXCR4 is essential for T-tropic (X4) HIV-1 entry.
- HIV-1 infection remains a significant global health challenge.
- Targeting viral entry pathways is a key therapeutic strategy.
Purpose of the Study:
- To investigate the efficacy of an antisense phosphorothioate oligodeoxyribonucleotide (anti-S-ODN) in inhibiting CXCR4 gene expression.
- To evaluate the potential of anti-S-ODN as a therapeutic agent against X4 HIV-1 infection.
- To assess the role of nucleosomal histone proteins (RNP) in enhancing anti-S-ODN delivery and efficacy.
Main Methods:
- Synthesized and tested various anti-S-ODN sequences for their inhibitory effects on HIV-1 gag p24 production in HeLa-CD4 cells.
- Utilized a basic peptide transfection reagent, RNP, for the delivery of anti-S-ODN.
- Quantified the suppression of CXCR4 surface levels on treated cells to confirm sequence-specific inhibition.
Main Results:
- The anti-S-ODN-1 sequence demonstrated a notable inhibitory effect on HIV-1 gag p24 production.
- Encapsulation of anti-S-ODN-1 with RNP significantly enhanced its inhibitory activity compared to naked anti-S-ODN-1.
- Incubation with RNP-encapsulated anti-S-ODN-1 led to substantial suppression of CXCR4 surface expression, confirming sequence-specific gene silencing.
Conclusions:
- Antisense oligodeoxyribonucleotides targeting CXCR4 show promise for inhibiting HIV-1 replication.
- RNP-mediated delivery enhances the efficacy of antisense oligodeoxyribonucleotides.
- This approach presents a potential therapeutic avenue for managing HIV-1 infection by blocking viral entry.
Related Concept Videos
Experimental RNAi
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Inhibitors of Viral Protein Synthesis
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...

